Form 4: Armata Pharmaceuticals Director Jules Haimovitz Acquires Stock Options

Director Jules Haimovitz reports acquisition of stock options in Armata Pharmaceuticals.

Summary

• Jules Haimovitz, a director of Armata Pharmaceuticals, reported the acquisition of stock options on March 14, 2024.
• Haimovitz acquired 39,666 stock options that will vest upon the company's 2024 annual shareholders meeting, contingent on continuous service.
• An additional 54,343 stock options were acquired, vesting 50% on March 14, 2025, and 50% on March 14, 2026, also subject to continuous service.
• The exercise price for all options is $3.38.
• Following the transaction, Haimovitz directly owns 94,009 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director generally indicates confidence in the company's future, but it's a routine transaction.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.
• The vesting schedule tied to continuous service incentivizes the director to remain with the company.

Future Outlook

The vesting of the stock options is contingent upon the director's continuous service, suggesting an expectation of continued involvement with the company.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded companies, particularly in the biotech and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Biogen often use stock options to incentivize their executives and directors.
• The vesting schedules, typically tied to service or performance milestones, are also standard practice in the industry.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder sentiment.
• The vesting schedule incentivizes the director to remain with the company, benefiting employees and other stakeholders.

Next Steps

• The 39,666 options will vest upon the company's 2024 annual shareholders meeting, subject to the director's continuous service.
• The remaining 54,343 options will vest in two tranches on March 14, 2025, and March 14, 2026, respectively, also subject to continuous service.

Key Dates